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Including herbal medicine, complementary and alternative medicine (CAM) is popular worldwide. The traditional Chinese med-
icine xinkeshu has been widely used to treat coronary heart disease in China. This study was designed to investigate the protective
eﬀect and probable mechanism of xinkeshu tablet to atherosclerotic myocardial ischemia rabbit. Rabbits were divided into four
groups (n = 12 each) and fed with diﬀerent diet for 12 weeks: Control (standard diet), Model (high-cholesterol diet), XKS (high-
cholesteroldietwith184.8mg/kg/dxinkeshu),andAtorvastatin(high-cholesteroldietwith5.0mg/kg/datorvastatin).Plasmalipo-
protein,ECG,endothelium-dependentvesselrelaxation,histomorphologicalstudy,andexpressionsofeNOSandVCAM-1oncor-
onary arteries were assessed. The ﬁndings showed that, similar to atorvastatin, xinkeshu presented signiﬁcant eﬀects on rescuing
endothelium-dependent vessel relaxation, inhibiting atherosclerotic progress, preventing myocardial ischemia, and changing
eNOSandVCAM-1expression.However, xinkeshushowednolipoproteinloweringeﬀectinhypercholesterolemia rabbits.There-
sults of the present study indicated that xinkeshu exerted potent antiatherogenic and anti-ischemic properties on atherosclerotic
myocardial ischemia rabbit. An endothelial protecting eﬀect may be involved in the mechanism other than antihyperlipidemic
eﬀect.
1.Introduction
Coronary heart disease (CHD) is caused by atherosclerosis
mainly, and high cholesterol levels play an important role in
the onset of this disease [1]. The causes of atherosclerosis
appear to be lipid retention, oxidation, and modiﬁcation,
which provoke chronic inﬂammation at susceptible sites in
the walls of all major conduit arteries [2]. Although much
progress has been made in reducing mortality from CHD,
thisconditionremainstheleadingcauseofdeaththroughout
the world [3]. Statins are the most potent drugs in this
area. Studies have revealed that statins may not only lower
low-density lipoprotein (LDL), but also elevate high-density
lipoprotein (HDL) and enhance vascular endothelial func-
tion [4, 5]. However, liver dysfunction and myolysis as side
eﬀects of statins caused some patients to withdraw from
treatment [6]. Complementary and alternative medicine
(CAM), including herbal medicine, is popular in the general
population worldwide [7, 8]. A number of herbs or plants
with potent therapeutic components have been investigated
fortheirantihyperlipidemic,antioxidant,andantiatheroscle-
rotic properties [9–14]. The use of herbal medicine for the
treatment of various disorders including heart diseases has a
long and extensive history.
In China, Traditional Chinese herbal products with low
side eﬀects are of high interest as CAM therapy to CHD [15–
17].Traditional Chinese medicine (TCM) xinkeshu (XKS) in
tablet is a compound prescription formulated according to
the meridian theory of TCM and approved in 2005 by the
State Food and Drug Administration of China as a treatment2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: The experimental design. H-ChE, 2% cholesterol ester;
XKS, Xinkeshu; VP, vasopressin; ECG, electrocardiogram; EDVR,
endothelium-dependent vessel relaxation; eNOS, endothelial nitric
oxide synthase; VCAM-1, vascular cell adhesion molecule 1.
of angina pectoris and arrhythmia patients in the clinic.
Here, we have further investigated the mechanism of treat-
ment with XKS tablet to atherosclerotic rabbits. Outcome
can be summarized as follows: blood plasma lipoprotein
levels; ECG test, indicator of severity of myocardial ischemia
[18]; endothelium-dependent vessel relaxation (EDVR); his-
tomorphological studies; expressions of endothelial nitric
oxide synthase (eNOS) and vascular cell adhesion molecule
1 (VCAM-1) on coronary arteries, markers of endothelial
function [19, 20].
2.MaterialsandMethods
2.1. Drugs and Reagents. XKS tablets were from Wo Hua
Pharmaceutical Co, CHN. Cholesterol was from Tian Qi
Chemical Engineering Co, CHN. Atorvastatin was from Jia
Lin Pharmaceutical Co, CHN. Vasopressin (VP), phenyle-
phrine (PE), and acetylcholine (Ach) were from Sigma, USA.
PolyclonalImmunohistochemicalgoatanti-rabbiteNOSand
VCAM-1 antibodies were from Santa Cruz, USA. Strepta-
vidin/peroxidase kit and biotinylated mouse anti-goat IgG
were from Boster, China.
2.2. Animals and Experimental Design. Japanese big ear rab-
bits(2.25±0.20kg,aged3weeks,male)werepurchasedfrom
the Laboratory Animal Institute of the Chinese Academy of
Medical Science. They were single-housed under a 12:12h
light-dark cycle, temperature-(23 ± 2◦C) and humidity
(50%±10%) controlledspeciﬁcpathogen-freeenvironment,
with water available ad libitum. All animal care and exper-
imental protocols complied with the Animal Management
Rules of the Chinese Ministry of Health, and the study was
approved by the animal ethics committee of the Chinese
AcademyofMedicalSciences.Standarddietpelletsandhigh-
cholesterol ester (H-ChE) diet [21] pellets which contain
2% cholesterol (240–280g/d) for rabbits were prepared by
Beijing Scientiﬁc Animal Feedstuﬀ Company.
Rabbits were divided into 4 groups (n = 12 per group)
and the experimental design was presented in Figure 1.
Control. Rabbits were continuously fed with the standard
pellets for 12 weeks. Rabbits were administrated intragastri-
cally with normal saline (10mL/kg/d).
Model. Rabbits were continuously fed with the H-ChE diet
pellets. The others were the same as the Control.
XKS. Rabbits were administrated intragastrically with
184.8mg/kg/d XKS (equivalent dose for an adult with mean
weigh of 60kg) in normal saline (10mL/kg/d). The others
were the same as the Model.
Atorvastatin. Rabbits were administrated intragastrically
with5.0mg/kg/datorvastatininnormalsaline(10mL/kg/d).
The others were the same as the Model.
2.3. Plasma Lipoprotein Analysis. Fasting venous blood sam-
ples were collected in heparin from the marginal vein before
and after the 12 weeks experiments. Plasma was separated
a n ds t o r e da t−20◦C. Plasma lipoprotein levels, including
total cholesterol (TC), triglycerides (TG), LDL, and HDL
were measured by use of an automatic biochemistry analyzer
(Dimension AR, DuPont, USA).
2.4. ECG Test on VP-Induced Myocardial Ischemia Model. At
the end of the 12-week experimental period, according to
the method of Serradeil-Le Gal et al. [22], experimental of
coronary vasospastic myocardial ischemia was induced by
VP. The standard limb lead II of the ECG was recorded con-
tinuously before and 25min after the administration of VP
(2.0IU/kg, iv.) with a Powerlab 30 system (AD Instruments,
Castle Hill, Australia).
2.5. Assessment of EDVR. One week after the ECG tests were
ﬁnished, rabbits (n = 6 per group) were anesthetized by 10%
chloral hydrate (25mg/kg, ip). According to the method of
Lee et al. [23], the fresh hearts were immediately obtained
and stored in cold PBS. Then the abdominal aortas were
dissected and cut into 3mm rings. The rings were stretched
to 1.5g tension and allowed to equilibrate for 60min in
a1 0 m Lt i s s u eb a t h( 3 8 . 6 ◦C) containing Krebs-Henseleit
solution (composition in mM: 115 NaCl, 25 NaHCO3,1 . 3 8
NaH2PO4,2 . 5 1K C l ,2 . 4 6M g S O 4, 1.91 CaCl2, and 5.56
dextrose) and aerated with a mixture of 95% O2 and 5%
CO2. Force generation was monitored by use of an isometric
transducer connecting with the Powerlab 30 system. After
equilibration, vasoconstriction was induced with 10−6 MP E .
Once maximal contraction had reached a plateau, EDVR was
determined as the response from 10−9 to 10−4 MA c h .T h e
percent relaxation was calculated based on changes in the
tension to the maximal precontraction value induced by PE.
2.6. Histomorphological Studies. The other rabbits (n = 6pe r
group) were anesthetized by 10% chloral hydrate (25mg/kg,
ip).Perfusionﬁxationwasperformedtoeveryrabbitthrough
the left common carotid artery with heparinized normal
saline (70mL/kg) and 4% paraformaldehyde (140mL/kg)
in 0.1M phosphate buﬀe rb yu s eo fa na o r t i cc a t h e t e rEvidence-Based Complementary and Alternative Medicine 3
(atabout100mmHgpressure),meanwhiletheexternaljugu-
lar vein was cut for eliminating remained blood. Two hours
later under 4.0◦C, hearts and aortas were removed and im-
mersion-ﬁxed in 10% buﬀered formalin overnight.
The aortas were opened longitudinally along the poste-
rior side and then stained with Sudan IV for visualization of
the atherosclerotic plaques. After staining, the aortas were
pinned open to ﬂatten them and photographed. The total
area (AT) and the plaques area (AP) of the aorta were mor-
phometrically analyzed by use of Image-Pro Plus 7.0 mor-
phometric analysis system (Media Cybernetics, USA). The
atherosclerotic plaques ratio was calculated as AP ÷ AT ×
100% [24].
Left circumﬂex coronary artery (2cm long) with the
adjacent myocardium tissues was carefully cut. Specimen
were embedded in paraﬃn and cut into 5µms e c t i o n so n
a microtome, and the cross sections were then stained with
hematoxylin and eosin (HE) and scanned by use of
NanoZoomer Digital Pathology image analysis system (Ha-
mamatus, Olympus, JAP). The area of the lumen (AL)a n d
the area bordered as the internal elastic lamina (AI)w e r e
morphometrically analyzed by use of the Image-Pro Plus 7.0
analysis system for ×200 magniﬁcations. The coronary ste-
nosis ratio was calculated as (AI −AL) ÷AI ×100% [25].
2.7. Immunohistochemical Studies of eNOS and VCAM-1 on
CoronaryArtery. eNOS and VCAM-1 expressions were eval-
uated immunohistochemically on coronary artery using the
streptavidin/peroxidase kit according to the manufacturer’s
instructions. Sections were deparaﬃnized, rehydrated, and
then soaked in antigen retrieval buﬀer (0.01M Tris-base,
1.0M EDTA, 0.05% Tween 20, pH 6.0) for 3min at 95◦C.
Endogenous peroxidase activity was blocked by incubating
the sections in 3% hydrogen peroxide aqueous solution for
1h at room temperature. The sections were rinsed thrice
with PBS, and then incubated with 100µL goat anti-rabbit
eNOS or VCAM-1 antibody. The sections were rinsed with
PBS and incubated with 100µL biotinylated mouse anti-
goat IgG (1:100 dilutions in PBS). Protein was visualized
with diaminobenzidine substrate solution. Primary antibody
was substituted by PBS in the negative controls. The eNOS
or VCAM-1staining area (AP) and observed area (AT)w e r e
morphometrically analyzed by use of the Image-Pro Plus 7.0
analysis system for ×400 magniﬁcation. The total existing
eNOS or VCAM-1 was calculated semiquantitatively as AP ÷
AT × 100% [26].
2.8. Statistical Analysis. Statistical analyses involved use of
SPSS, v13.0 (SPSS Inc., Chicago, IL, USA). Quantitative vari-
ables are expressed as means ± SEM. Comparison of con-
tinuous variables among multiple groups was performed by
analysis of variance with ANOVA, and post hoc comparisons
were made using LSD test.
3. Results
3.1. Plasma Lipoprotein Analysis. Before the 12-week exper-
iment, the baseline values of plasma lipoprotein levels (TC,
TG, LDL, and HDL) did not vary signiﬁcantly among the
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Figure 2: Max ST segment elevation in ECG after vasopressin ad-
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Figure 3: Heart rate curves after vasopressin administration.
four groups. After the 12-week experiment, Model group
rabbits showed signiﬁcant increment in the levels of TC
(P<0.01), LDL (P<0.01), TG (P<0.05) and signiﬁcant
reduction in the level of HDL (P<0.05) compared with
Control. Atorvastatin treatment for 12 weeks signiﬁcantly
reduced TC (P<0.01), LDL (P<0.01), and TG (P<0.05)
levels and signiﬁcantly increased HDL (P<0.05) level com-
pared with Model. However, XKS treatment showed a slight
reduction (P>0.05) in the TC, TG, LDL levels and a slight
increment (P>0.05) in the levels of HDL compared with
Model (Table 1).
3.2. ECG Test on VP-Induced Myocardial Ischemia Model.
Injection of VP (iv.) into conscious rabbits induced transient
ST segment elevation in the ECG in each group. The max-
imum ST segment elevation was observed 5–10min after
VP administration in Control. Model group rabbits showed
signiﬁcantly higher (P<0.01) ST segment elevation than
Control. XKS treatment showed signiﬁcant (P<0.01) anti-
ischemic eﬀect (inhibition of ST segment elevation induced4 Evidence-Based Complementary and Alternative Medicine
Table 1: Plasma lipoprotein levels before and after 12 weeks period experiment.
Parameters Before After
(mmol/L) Control Model XKS Atorvastatin Control Model XKS Atorvastatin
TC 1.37 ± 0.13 1.18 ± 0.12 1.24 ± 0.08 1.29 ± 0. 11 1.43 ± 0.05 27.83 ± 2.43aa 26.60 ± 0.30aa 17.19 ± 1.54aabbcc
TG 0.92 ± 0.18 1.01 ± 0.26 0.88 ± 0.12 0.95 ± 0.13 0.52 ± 0.03 2.11 ± 0.17a 1.58 ± 0.05a 0.69 ± 0.06bc
LDL 0.59 ± 0.01 0.64 ± 0.06 0.54 ± 0.08 0.57 ± 0.09 0.45 ± 0.01 15.11 ± 2.74aa 15.06 ± 2.16aa 7.63 ± 1.22aabbcc
HDL 3.54 ± 0.05 4.05 ± 0.06 3.81 ± 0.04 3.30 ± 0.02 3.49 ± 0.04 2.47 ± 0.15a 2.48 ± 0.16a 3.17 ± 0.15abc
Data are expressed as mean ± SEM, n = 12, aP<0.05 aaP<0.01 versus Control; bP<0.05 bbP<0.01 versus Model; cP<0.05 ccP<0.01 versus XKS.
Table 2: ST segment elevation (mV) on ECG after vasopressin administration.
Group Time (min)
2 5 10 15 20 25
Control 0.08 ± 0.01 0.19 ± 0.04 0.24 ± 0.05 0.17 ± 0.06 0.04 ± 0.01 0.02 ± 0.00
Model 0.07 ± 0.02 0.40 ± 0.12aa 0.56 ± 0.12aa 0.33 ± 0.08a 0.25 ± 0.12aa 0.07 ± 0.01
XKS 0.08 ± 0.01 0.27 ± 0.08ab 0.37 ± 0.10aabb 0.20 ± 0.10b 0.12 ± 0.10ab 0.04 ± 0.00
Atorvastatin 0.06 ± 0.01 0.38 ± 0.15abc 0.46 ± 0.11aabc 0.26 ± 0.09a 0.16 ± 0.06ab 0.06 ± 0.01
Data are expressed as mean ± SEM, n = 12, aP<0.05 aaP<0.01 versus Control; bP<0.05 bbP<0.01 versus Model; cP<0.05 versus XKS.
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Figure 4:Endothelia-dependent vesselrelaxationcurvesofabdom-
inal aorta rings.
by VP) than Model. Atorvastatin also showed signiﬁcant
(P<0.05) anti-ischemic eﬀect; however, XKS was more ef-
fective (P<0.05) than Atorvastatin (Table 2 and Figure 2).
Transient heart rate (HR) decrement occurred after VP
administration in each group. The eﬀect peaked after 10–
15min in Control. Model group rabbits showed more obvi-
ous HR decrement (P<0.05) compared with Control. XKS
treatment showed signiﬁcant (P<0.05) inhibition on HR
decrement compared with Model. However, no signiﬁcant
inhibition eﬀect (P>0.05) was observed with atorvastatin
treatment compared with Model (Figure 3).
3.3.AssessmentofEDVR. Ach (10−9 to10−4 M)causedacon-
centration-dependent relaxation in preconstricted abdomi-
nal aorta rings. The max EDVR was signiﬁcantly impaired
(P<0.01) in Model group rabbits compared with Control.
XKS and Atorvastatin treatment signiﬁcantly (P<0.05) at-
tenuated the impairment compared with Model. Atorvas-
tatin was more eﬀective (P<0.05) than XKS (Figure 4).
3.4. Histomorphological Studies. None of Control group rab-
bits showed any abnormal histological changes in the aorta.
Typical macroscopic atherosclerotic plaques on the intimal
surface of aortas can be seen distinctly and commonly in
Model rabbits. Atherosclerotic plaques became red color by
Sudan IV staining. XKS and Atorvastatin treatment signiﬁ-
cantly (P<0.05) reduced the atherosclerotic plaques area
compared with Model. The eﬀect was similar (P>0.05)
between the two groups (Figure 5).
No atherosclerotic changes of any arterial wall were pre-
sented in Control group rabbits. But in Model rabbits, some
intramyocardial small arterioles showed signiﬁcant athe-
rosclerotic changes, including that the basal laminae around
the smooth muscle cells were irregularly thickened and mul-
tilaminated. The collagen ﬁbrils had signiﬁcantly increased
inthemedia,andalargenumberoflipidshadinﬁltratedinto
the thickened intima. The coronary lumens became stenosis
accompanied with lipids deposition that contained foam
cells. Model group rabbits showed signiﬁcant (P<0.01) cor-
onarystenosisthanControl.XKSandAtorvastatintreatment
signiﬁcantly (P<0.05) inhibited the coronary stenosis com-
pared with Model. The eﬀect was similar (P>0.05) between
the two group (Figure 6).
3.5. Immunohistochemistry Studies of eNOS and VCAM-1 on
Coronary Artery. In Control group, the eNOS positive stain-
ing could be observed in the cytoplasm of coronary inti-
mal layer area. The existing of eNOS was signiﬁcantly
decreased (P<0.01) in Model group compared with Con-
trol. XKS and Atorvastatin treatment signiﬁcantly (P<
0.01) increased the existing eNOS compared with Model.
Atorvastatin was more eﬀective (P<0.05) than XKS
(Figure 7).Evidence-Based Complementary and Alternative Medicine 5
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Figure 5: Atherosclerotic plaques on the intimal surface of aorta by Sudan IV staining.
C
o
r
o
n
a
r
y
s
t
e
n
o
s
i
s
r
a
t
i
o
(
%
)
Control
Control
Model
Model
XKS
XKS
Atorvastatin
Atorvastatin
∗
∗
∗
∗
∗∗
∗P<0.05 ∗∗P<0.01
100
75
50
25
0
100um 100um
100um 100um
Figure 6: Coronary stenosis by HE staining (light micrographs, middle 100×, left top 400×).
In Control group, VCAM-1 positive staining was seldom
observed in the entire wall of coronary artery. However, it
could be observed largely in collagen ﬁbrils and foam cells
richareaofthevascularwallinModelgroup,andtheexisting
of VCAM-1was signiﬁcantly (P<0.01) increased than Con-
trol. XKS and Atorvastatin treatment signiﬁcantly (P<0.01)
decreased the existing of VCAM-1 compared with Model.
XKS was more eﬀective (P<0.05) than Atorvastatin
(Figure 7).
4. Discussion
CAM including herbal medicine has gained a worldwide
popularity over the past 20 years. It is argued that patients
with chronic conditions including cardiovascular disease are
likely to use CAM [27, 28]. Herbal medicine is the method
with the use of medicinal plants or herbs for prevention
and treatment of diseases, and it ranges from traditional and
popular medicines of every country to the use of standard-
ized and titrated herbal extracts [29].
XKS tablet was being widely used to treat CHD by the
traditionalpractitionersinChinaovertenyears[30].Clinical
research revealed that XKS carried many biological activities,
including improving of heart rate variability, reducing the
episode of angina pectoris, improving the arterial elasticity
[31,32].Meanwhile,pharmacologicalbasicresearchrevealed
that XKS administration had a variety of therapeutic eﬀects
such as decreasing myocardial oxygen consumption, lower-
ing lipid, and antiapoptosis [33–35].
In the present study, atorvastatin was chosen as a positive
control therapy. The ﬁndings showed that atorvastatin treat-
ment for 12 weeks was very eﬀective in lowering the plasma
TC and LDL levels, increasing HDL level, lessening experi-
mental myocardial ischemia, rescuing EDVR, and inhibiting
atherosclerotic progress. XKS treatment for 12 weeks pre-
sented the similar eﬀects on rescuing EDVR and inhibit-
ing atherosclerotic progress as atorvastatin did. Even XKS6 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Existing of eNOS and VCAM-1 on coronary artery by immunohistochemistry staining (light micrographs, 400×).
was more eﬀective on preventing myocardial ischemia and
maintaining the cardiac rhythm than atorvastatin. Maybe
these properties were the main mechanisms of XKS for clin-
ical angina pectoris and arrhythmia therapy [31, 32]. On the
other hand, one of the important ﬁndings in the present
study was that no signiﬁcant changes in lipid proﬁles oc-
curred in the rabbits administered with XKS. In other words,
XKS showed no lipoprotein lowering eﬀect to the hyperc-
holesterolemia induced by H-ChE diet.
It is well known that endothelial injury is a key event
in the pathogenesis of atherosclerosis. Atherosclerosis can
be induced from simple dysfunction of endothelial lining as
occurs with hypercholesterolemia [36]. Endothelial cell ho-
meostasis is maintained largely through the synthesis of
nitric oxide (NO), a potent vasodilator synthesized by eNOS.
NO serves important functions, including regulation of
vascular tone and regional blood ﬂow and suppression of
vascular smooth muscle cell proliferation. eNOS is aﬀected
bydiﬀerentstimuli,includinghypoxia,shearstress,LDL,and
thedevelopmentandprogressionofatherosclerosis[37].The
decreasing expression or inactivation of eNOS is recognized
to be a crucial factor in the development of endothelial dys-
function [19]. The important role of vascular adhesion
molecules in atherosclerosis has been discovered and these
molecules play an important role in adhesion of circulating
leukocytestoendothelium,whichistheﬁrststepininitiation
of atherosclerosis [38]. As a transmembrane glycoprotein,
VCAM-1 is upregulated and expressed at atherosclerosis-
prone sites even before macroscopic disease is apparent, with
persistent expression in more advanced atherosclerotic
lesions. Atherogenic diet could rapidly induce VCAM-1 ex-
pression in aortic endothelium in aortic organ cultures [20].
According to the novel property of antiatherogenic and
antiischemia notviaantihyperlipidemia pathway,wefocused
on endothelial protection as the target to investigate the
indeed mechanism of XKS. eNOS and VCAM-1 were picked
as antiatherogenic and atherogenic factors, respectively.
The ﬁndings showed that the 12 weeks of H-ChE dietEvidence-Based Complementary and Alternative Medicine 7
Table 3: Formulation of xinkeshu tablet.
Latin binomial Herb or plant sources Part used Portion (%)
Radix salviae miltiorrhiae Salvia miltiorrhiza Bge. Root and rhizome 32
Panax notoginseng Panax Notogin seng (Burk) F.H Chen Root and rhizome 2
Hawthorn Crataegus pinnatiﬁda Bge. Fruit 32
Radix Puerariae Pueraria lobata Root and rhizome 32
Radix Aucklandiae Aucklandia lappa Decne. Root and rhizom 2
caused decreasing expression of eNOS as well as increasing
expression of VCAM-1during the procedure of atherosclero-
sis. Atorvastatin and XKS treatment both showed vascular
protecting property by changing the expression of eNOS
andVCAM-1.Therefore,signiﬁcantendothelia protectionto
vascular was probably one of the important mechanisms in-
volved in cardioprotective properties of XKS.
XKS includes 5 herbal medicinal components, and they
are Salvia miltiorrhiza Bunge, Panax notoginseng (PN),
Fructus Crataegi, Radix Puerariae,a n dRadix Aucklandiae
(Table 3). Materials were originally ground to a ﬁne powder
by a micronizer and prepared as tablet, which were authen-
ticated and standardized on the basis of marker compounds
in the Chinese Pharmacopoeia 2010 [39] .S e v e r a lg r o u p so f
monomer with special biological activities were extracted
from each single component, for example, attenuating pul-
monary ﬁbrosis of PN extract [40], lowering plasma choles-
terol of Hawthorn extract [41], improving insulin resistance
of Puerarin extract [42], and attenuating idiopathic edema
of radix Aucklandiae extract [43]. According to the theory
of TCM, Salvia miltiorrhiza Bunge was looked on as a kind
of “principal drug”, Panax notoginseng as “ministerial drug”,
and the other 3 components served as “adjunctive drug”
among components of XKS [44]. Tanshinone IIA was one
of the most important monomer ingredients of Salvia mil-
tiorrhiza Bunge extract [45]. The biological activities of
Tanshinone IIA were about decreasing myocardial oxygen
consumption [46], dilation of coronary arteries [47], and
improving neuron regeneration [48], antihypertension [49],
and antioxidant [50].
In the present study, we looked on XKS as a single
“medicine” and investigated the pharmacological action of
all components together. Although the results of present
studyprovidedimpetusforfurtherstudiesonthetherapeutic
action of XKS, the relationship of these components and
their interactions remained to be clariﬁed. Those were the
main limitations of the present study. Therefore, the detailed
molecular mechanism of XKS and further studies in animals
aboutthe pharmacologicalof theactive ingredients andmet-
abolites should be investigated.
5. Conclusion
In conclusion, it was explicitly demonstrated that TCM XKS
exerted potent antiatherogenic and anti-ischemic properties
on the atherosclerotic myocardial ischemia rabbit model.
An endothelial protecting eﬀect may be involved in the
mechanism other than antihyperlipidemic eﬀect. We be-
lieved that a better understanding of the mechanisms by
which XKS protecting endothelia and the interactions of
active ingredients could lead to novel pharmacological CAM
interventions for CHD patients.
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